The Ministry of Health, Labor and Welfare has purchased the amount required to stockpile 2 million people as planned for "Abigan," which is under review for approval as a treatment for the new coronavirus.
The cost is 13.9 billion yen, and the Ministry of Health, Labor and Welfare states that "it was deemed necessary from the perspective of crisis management."
"Abigan" was developed as a remedy for the new strain of influenza, and in April last year, the government stockpiled 2 million people by the end of this year, saying that it could be expected to have an effect on the new coronavirus, which had a limited remedy at that time. I have put together a plan to do.
According to the Ministry of Health, Labor and Welfare, in January, we purchased 550,000 people from Fujifilm Toyama Chemical and signed a contract to purchase another 790,000 people on the 19th.
The total purchase cost is 13.9 billion yen, which means that we have secured 2 million people as planned, including the 700,000 people we have already stockpiled.
On the Abigan, last December, see off the Ministry of Health, Labor and Welfare of the Expert Group is the approval of propriety as "It is difficult to clearly determine the validity of the data of the moment" decision, it stood the prospect of time to be approved not.
In addition, the amount used in the observational study for about one year until the end of last month was 10,800 people nationwide, which was only about 0.5% of the planned stockpile, and the plan was re-planned by experts in infectious disease control. There were voices pointing out the need for consideration.
The Ministry of Health, Labor and Welfare said, "In addition to the fact that pharmaceutical companies were already preparing contracts, we decided that it was necessary from the perspective of crisis management amid the spread of infection. If approved, we would like to use it as a therapeutic drug." I am commenting.